Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children

Keklíkçí, Uğur; Söker, Sevda; Şakalar, Yıldırım Bayezit; Ünlü, Kaan; Özekinci, Selver; Tunik, Selcuk

doi:10.1007/s10384-008-0577-z

Cited by 42 publications

(44 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(18) There are several studies about low-dose topical CsA therapy for AKC and VKC. (9,(19)(20)(21) A study by Ozcan et al, which examined the use of topical CsA 0.05% in seven cases of severe allergic conjunctivitis, found significant reductions in the symptom and sign scores, and a reduction in the demand for corticosteroids, with no side effects observed. (19) In a placebo-controlled, doublemasked study, no significant difference was detected in the symptom, sign and drug scores of the 40 patients with either AKC or VKC after three months of treatment with topical CsA 0.05%; no side effects were reported.…”

Section: A 2bmentioning

confidence: 99%

“…(9) Keklikci et al reported reductions in the clinical scores and inflammatory cell counts (using conjunctival impression cytology) of 54 patients after three months of topical CsA 0.05% therapy, with no side effects. (20) A study conducted by Takamura et al, involving 2,597 patients with VKC who were treated with CsA 0.1% for six months, reported decreased clinical scores and the disappearance of steroid demand in one-third of the patients; additionally, 7.4% of them experienced ocular irritation and 1.4% had ocular infections. (21) In the present study, the use of CsA 0.05% resulted in reduced steroid demand, with no serious side effects detected.…”

Section: A 2bmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Yücel¹,

Ulus²

2016

smedj

View full text Add to dashboard Cite

RESULTSAt baseline, the median values of the symptom and sign scores were 10.0 (range 5.0-18.0) and 6.0 (range 2.0-13.0), respectively. At Week 4 of treatment with topical CsA 0.05%, the median values of the symptom and sign scores were 3.0 (range 0-14.0) and 3.0 (range 0-8.0), respectively. The reductions in the symptom and sign scores were statistically significant. The reduction in the need for corticosteroid was statistically significant by Week 12 of therapy. No significant side effects were reported.CONCLUSION Topical CsA 0.05%, which can help to reduce corticosteroid usage, is an effective and safe alternative for the treatment of resistant VKC. Further studies are needed to determine the optimal duration of therapy and possibility of recurrence.

show abstract

Section: A 2bmentioning

confidence: 99%

Section: A 2bmentioning

confidence: 99%

Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Yücel¹,

Ulus²

2016

smedj

View full text Add to dashboard Cite

show abstract

“…Several comparative studies between antiallergy medications and design model studies suggested topical treatment of Olopatadine hydrochloride for use in allergic eye diseases. The effects of Olopatadine in the treatment of allergic conjunctivitis on signs such as itching and redness were shown [14][15][16]. When the antihistaminic medications were compared, it was reported that Olopatadine hydrochloride 0.1% caused less discomfort for patients during the use of the drug [3].…”

Section: Discussionmentioning

confidence: 99%

“…It has also been shown that Cyclosporine A is effective in causing regression of the objective symptoms, particularly the giant papillae on the tarsal conjunctiva due to VKC [26,27]. The inhibitory effect of Cyclosporine A in the development of conjunctival fibrosis is previously known [16]. Cyclosporine A inhibits the development of corneal vascularization [28].…”

Section: Discussionmentioning

confidence: 99%

Topical Use of Olopatadine and Cyclosporine a in Treatment of Vernal Keratoconjunctivitis

Knatova¹,

Kantarcı²,

Akata³

et al. 2016

Ann Clin Anal Med

View full text Add to dashboard Cite

with Cyclosporine A ophthalmic solution (0.05%) in treating the signs and symptoms of VKC. Material and Method: Twenty-five patients with VKC were included in a prospective study. One eye of each patient was treated with Olopatadine while the other eye was treated with Cyclosporine A. Subjective symptoms of the patients such as itching, tearing, foreign body sensation, and mucus discharge were recorded and scored. The objective signs, such as the presence of giant papillae on the tarsal conjunctiva, bulbar conjunctival hyperemia, keratitis, limbal hypertrophy, corneal vascularization, and conjunctival cicatrization, were scored. Results: There was no significant difference between the Olopatadine group and the Cyclosporine A group regarding subjective symptoms at the 3rd, 6th, 12th, and 18th month. There was a significant improvement in the subjective symptoms of both groups. No significant difference was seen between the groups with regard to objective signs. A significant improvement was observed in the Cyclosporine group in the late period of the study. Discussion: In long-term therapy of VKC, similar effects were seen regarding improvement in the subjective symptoms during the use of topical Olopatadine and Cyclosporine A. In terms of improvement regarding the objective signs, Cyclosporine A was seen to be more effective in the late period.

show abstract

“…The low dose (cyclosporine A 0.05%) had mixed results in the alleviation of ocular itching and/or other symptoms of chronic AC [Akpek et al 2004;Kosrirukvongs and Luengchaichawange, 2004;Daniell et al 2006;Keklikci et al 2008;Erdinest and Solomon, 2014;Wu et al 2014]. Tacrolimus, with a potency 100-fold that of cyclosporine, blocks cellular steroid receptors, inhibiting mediator release from mast cells and, thereby, suppressing T-cell activation and consequent B-cell proliferation (late-phase allergic responses) [Sawada et al 1987;Erdinest and Solomon, 2014].…”

Section: Immunomodulatorsmentioning

confidence: 99%

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management

Ackerman

Smith

Gomes

2016

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Allergic conjunctivitis is one of the most common allergic conditions worldwide. Its incidence is increasing due to changing climate, pollution, increased pollen loads, and the subject's heightened immunological sensitivity in response to these environmental changes. The pathophysiology predominantly involves immunoglobulin E-related mast-cell activation, with release of histamine and other mediators contributing to the propagation of the response by calling in other immune cells and further inflammation. This article presents the evolution of ocular allergy treatments, from vasoconstrictors, to antihistamines and mastcell stabilizers, to the dual-acting agents, as well as corticosteroid and immunomodulatory options. Future targets for allergy treatment are also discussed.

show abstract

Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children

Abstract: Topical CsA 0.05% eyedrops were found to be safe and effective in the treatment of patients with VKC. Consistent with these results, topical CsA may efficiently reduce conjunctival inflammation in severe VKC.

Cited by 42 publications

References 32 publications

Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Topical Use of Olopatadine and Cyclosporine a in Treatment of Vernal Keratoconjunctivitis

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management

Contact Info

Product

Resources

About